Header Logo

Connection

KENNETH MCCLAIN to Mutation

Back to Details
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Mutation.
KENNETH MCCLAIN
Connection Strength
1.185
Mutation
  1. Mixed histiocytic disorders: Nature versus nurture? Br J Haematol. 2024 Jul; 205(1):20-21.
    View in: PubMed
    Score: 0.331
  2. fHLH: becoming a blended family. Blood. 2014 Aug 21; 124(8):1210-1.
    View in: PubMed
    Score: 0.169
  3. Why do T cells cause so much trouble? Blood. 2014 Mar 27; 123(13):1978.
    View in: PubMed
    Score: 0.164
  4. BRAF V600E vs cell of origin: what governs LCH? Blood. 2021 10 07; 138(14):1203-1204.
    View in: PubMed
    Score: 0.069
  5. Histiocytic Diseases of Neonates: Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Juvenile Xanthogranuloma. Clin Perinatol. 2021 03; 48(1):167-179.
    View in: PubMed
    Score: 0.066
  6. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):395-399.
    View in: PubMed
    Score: 0.065
  7. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.050
  8. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.049
  9. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015; 2015:177-82.
    View in: PubMed
    Score: 0.043
  10. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.041
  11. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.029
  12. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
    View in: PubMed
    Score: 0.018
  13. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 05 28; 135(22):1929-1945.
    View in: PubMed
    Score: 0.016
  14. BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Blood Adv. 2019 06 25; 3(12):1848-1853.
    View in: PubMed
    Score: 0.015
  15. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018 06 28; 131(26):2877-2890.
    View in: PubMed
    Score: 0.014
  16. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.013
  17. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.013
  18. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015 Jan 22; 125(4):591-9.
    View in: PubMed
    Score: 0.011
  19. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.